| Feb 8 2024 |
Fraud May Not Always Unravel All–What Does the Contract Say? |
K&L Gates LLP |
| Feb 7 2024 |
Opioid Treatment Programs: SAMHSA Makes Permanent Regulatory Flexibilities |
Foley & Lardner LLP |
| Feb 7 2024 |
FDA Announces Update to Fruit Pouch Contamination Investigation |
Keller and Heckman LLP |
| Feb 7 2024 |
Regulatory Compliance Is Now More Accessible for the Cannabis and Hemp Insurance Market |
Wilson Elser Moskowitz Edelman & Dicker LLP |
| Feb 6 2024 |
New California Bills Would Require Naloxone in the Workplace to Respond to Drug Overdoses |
Ogletree, Deakins, Nash, Smoak & Stewart, P.C. |
| Feb 6 2024 |
5 Trends to Watch: 2024 Class Actions |
Greenberg Traurig, LLP |
| Feb 6 2024 |
New SAMHSA Rule Expands Access to Medications for the Treatment of Opioid Use Disorder |
Polsinelli PC |
| Feb 6 2024 |
China Solicits Comments on Food Labeling Standard |
Keller and Heckman LLP |
| Feb 6 2024 |
Florida Governor Supports Lab-Grown (Cultivated) Meat Ban |
Keller and Heckman LLP |
| Feb 6 2024 |
Unpacking Averages: Device Manufacturers Should Use the Newly Released Demographic Data in MDRs to Ensure Their Devices Are Not Disproportionately Hurting Minorities |
Epstein Becker & Green, P.C. |
| Feb 6 2024 |
FDA’s Office of Prescription Drug Promotion Issues Its First Untitled Letter of the Year to Novartis for Misleading Statement Relating to KISQALI® |
Sheppard, Mullin, Richter & Hampton LLP |
| Feb 5 2024 |
Cannabis Rescheduling: HHS Findings and Legal Implications |
Sheppard, Mullin, Richter & Hampton LLP |
| Feb 5 2024 |
Don’t Assume Nonalcoholic Beverage Ingredients Are OK for Alcoholic Beverages |
McDermott Will & Schulte LLP |
| Feb 5 2024 |
Healthcare Preview for the Week of: February 5, 2024 [PODCAST] |
McDermott Will & Schulte LLP |
| Feb 5 2024 |
EPA Formally Reinstates All Chlorpyrifos Tolerances but Signals It Will Revoke Most of Them in the Future |
Beveridge & Diamond PC |
| Feb 5 2024 |
Court Finds Red Cross Has Antitrust Immunity, Rejecting Broad Interpretation of the Sherman Act |
McDermott Will & Schulte LLP |
| Feb 5 2024 |
2023 Retail Industry Year in Review |
Hunton Andrews Kurth |
| Feb 2 2024 |
McDermottPlus Check-Up: February 2, 2024 |
McDermott Will & Schulte LLP |
| Feb 1 2024 |
EuropaBio Publishes Biomanufacturing Global Series Reports on the United States, India, and Japan |
Bergeson & Campbell, P.C. |
| Feb 1 2024 |
Illinois to Ban Certain Food Additives, Following California, New York, and New Jersey |
Keller and Heckman LLP |
| Feb 1 2024 |
Bringing A New Healthy Food Ingredient to Market: Understanding the Regulatory Pathways |
Foley & Lardner LLP |
| Jan 31 2024 |
FDA Revises Draft HARPC Guidance |
Keller and Heckman LLP |
| Jan 31 2024 |
OIG Permits Medical Device Manufacturer’s Cost-Sharing Subsidies for Medicare Beneficiaries in Clinical Trial |
Sheppard, Mullin, Richter & Hampton LLP |
| Jan 30 2024 |
Blue Diamond “Smokehouse” Almonds Challenged |
Keller and Heckman LLP |
| Jan 30 2024 |
China’s Supreme People’s Court Upholds 79 Million RMB Win for Château Lafite Rothschild in Wine Trademark Case |
Schwegman, Lundberg & Woessner, P.A. |
| Jan 29 2024 |
Gold Dome Report – Legislative Day 10 (2024) |
Nelson Mullins |
| Jan 29 2024 |
2024 Top-of-Mind Issues for Life Sciences Companies |
Sheppard, Mullin, Richter & Hampton LLP |
| Jan 26 2024 |
FDA Takes First Step Toward International Regulation of Gene Therapies to Treat Rare Diseases |
Greenberg Traurig, LLP |
| Jan 25 2024 |
FDA Lists Regulations Under Development and Updates Priority Guidance Topics for Foods Program |
Keller and Heckman LLP |
| Jan 25 2024 |
An Overview of the US Food and Drug Administration's Legislative Goals (Part I) |
K&L Gates LLP |
| Jan 25 2024 |
A New Era For New Jersey’s Liquor Law: Comprehensive Reforms Enacted |
Norris McLaughlin P.A. |
| Jan 24 2024 |
CY 2024 OPPS Final Rule Summary for RI Year-End Review |
Polsinelli PC |
| Jan 24 2024 |
“No Preservatives” Claim Challenged |
Keller and Heckman LLP |
| Jan 24 2024 |
High Expectations: New Jersey’s Rocky Road to Cannabis Consumption Lounges |
Norris McLaughlin P.A. |
| Jan 23 2024 |
Select Highlights from CY 24 Medicare Physician Fee Schedule Final Rule |
Polsinelli PC |
